The federal government’s failed collaboration with a vaccine manufacturer in China at the beginning of the epidemic has led to a nearly two-year delay in attempting to create a COVID-19 vaccine manufactured in Canada.
Government documents obtained from him Fifth Estate Canadian authorities wasted months on the proposed vaccine from China for further testing and show that millions have been spent on improving a manufacturing facility that did not produce a million COVID-19 vaccine.
In early May 2020, the National Research Council of Canada (NRC) signed an agreement with Tianjin-based Casino Biologics to “rapidly detect the availability of the Covid-19 vaccine in Canada for emergency epidemic use.”
The carcino vaccine, developed by the Chinese Army’s Scientific Research Division, will be shipped to Canada for human experiments. If successful, the vaccine, which gave NRC $ 44 million to upgrade, would be made at a temporary facility in Montreal.
- View: Fifth Estate | Vaccine: What’s Wrong? -Tv & gem on Thursday at 9pm
Records reveal that the NRC, the Canadian government’s scientific research arm, is gearing up for vaccine production – which is expected to reach production levels by the summer of 2020 – before the contract is signed and human trials begin.
First, the NRC was producing doses for human trials in Canada, and then, under the agreement, “when frontline responders and Canadians were available.”
“Once fully operational, if the casino continues, the NRC will be able to produce 70,000 to 100,000 doses per month,” the NRC briefs said.
Dr. Kerr is the director of the Canadian Vaccineology Center in Halifax. NRC asked Scott Halperin to design clinical trials for CanSino in Canada.
“NRC and Carcino had a previous collaboration before the epidemic,” Halperin said in an interview Fifth Estate. “It was leveraged to a working relationship: ‘Can it extend to the current crisis?’ “
The vaccine stuck in China
Records show that as the months go by, the NRC facility is working to increase the number of publicly available quantities.
But ultimately, the CanSino vaccine is not available in Canada.
On May 16, 2020, Prime Minister Justin Trudeau announced the deal to Canadians. But later that month, a federal government memo states that the Canadian embassy in Beijing is still working to clear the vaccine from Chinese customs.
“CanSino vaccines are still in customs in China,” the memo said. “There is one at the embassy [meeting] Tomorrow. Imagine they get through customs [tomorrow], They can be put on the plane on the 27th.
But the vaccine candidate was not placed on the plane on May 27.
On the same day, Huawei CFO Meng Wang Zhou Zhou appealed to the BC Supreme Court to argue against his arrest at a high-tech tech executive in China. Meng was arrested in Vancouver in 2018 on charges of US bank fraud.
(Meng returned to China last month after signing a deferred prosecution agreement with the US Attorney General’s Office. Shortly thereafter, two Canadians in prison in China were allowed to return to Canada.)
“After all the things that happened, it was incredible to me that the government chose to partner with China, not just with Carcino,” said Conservative MP Michael Chong.
Chong served as a party’s foreign affairs critic and on the Canada-China relations parliamentary committee.
“By May 2020 it was clear that China was not a trusted partner,” he said.
On June 19, 2020, just weeks after Meng lost his court appeal, he accused Chinese Canadians Michael Kovrig and Michael Spawer of spying. He has already been held in Chinese prisons for no more than 500 days at no charge.
There was a verbal battle between governments in China and Canada, with the officials of each country criticizing the other.
View | McGill professors say China’s military contact is dangerous:
A security professor suspected that the customs vaccine had been stopped
Ben Fung, a security researcher at McGill University, tells Bob McCown of The Fifth Estate that a partnership with a company closely associated with the Chinese military is dangerous. 0:58
As of June 26, NRC bureaucrats have briefly acknowledged that “the shipment of vaccine material has stopped.”
As of early July, the CanSino candidate is still the only vaccine approved by Health Canada for human trials in Canada. NRC officials were hoping it would arrive later that month.
“CanSino is very committed to Canadian clinical trials,” the brief said.
By August, NRC records reveal, despite the fact that the vaccine candidate was “not yet approved by Chinese Customs to ship to Canada,” officials continued to work on production projects.
Customs is not a problem
Ben Fung, a security researcher and critic of China at McGill University in Montreal, was skeptical of the customs issue, and argued that Canada should be aware that the company’s link with the Chinese military and government is dangerous.
“So when they say the customs are stopping the vaccine, of course it’s not,” Fung said. “The [Chinese Communist Party] Is top management. “
View | Basic plans for the Carcino-Canada vaccine:
The Carcino-Canada Vaccine Project
Bob McCown of Fifth Estate is a CanSino-Canadian scientific consultant and long-time vaccine specialist Dr. Agency. 2:07
At the Center for Vaccineology, Halperin suspected the project was shrouded in diplomatic tensions between Canada and China. When he saw that the vaccine had been shipped to Pakistan and Russia without any problem, he knew the vaccine was not coming to Canada.
“Back then we knew it wasn’t the right paperwork and bureaucracy,” Halperin said. “It became clear that it was not, but eventually, it took another month or two to decide if it should be political. It couldn’t be anything else.”
The Globe and Mail first reported On August 25, 2020, the NRC abandoned its collaboration with Carcino because China would not allow vaccine doses to come to Canada.
View | CEO of CanSino on why the vaccine didn’t come to Canada:
Why the Cancino CEO vaccine didn’t come to Canada
Dr. Coleman, co-founder of Carcino. Xufeng Yu says he hoped to get vaccinated to Canada, where his family lives. He tells Bob McCown of the Fifth Estate how it opened. 1:19
In the interview with Fifth Estate, CanSino CEO Dr. Xuefeng Yu said he did not know why the vaccine was not sent to Canada.
“I don’t work for the government on either side. I don’t really know what’s going on behind the door of every country’s department.”
With shipping delayed by August, Yu said there was no point in pursuing trials in Canada. By that time, CanSino was already in the 3rd global trial elsewhere.
Millions of doses have been promised
Trudeau and Industry Minister Navdeep Bains held a press conference in NRC on August 31, 2020, promoting an upgraded Montreal laboratory to produce a carcino vaccine.
Although the federal government no longer has a vaccine partner, the Prime Minister’s Office announced that the facility “will allow the primary production of 250,000 dose vaccines per month beginning November 2020”.
However, the facility did not produce a 250,000 dose vaccine in November 2020, or any month thereafter.
“When the Prime Minister speaks, he knows what he is talking about and one hopes it is accurate,” NDP MP and health critic Dan Davis said in an interview Fifth Estate.
“So he was mistaken or he was misleading, and I think it’s up to him to explain what’s in it.
To date, no vaccines have been prepared at that NRC facility.
In August 2020, Trudeau announced that the new NRC laboratory in Montreal would produce two million doses a month by mid-2021.
It hasn’t even happened. According to the NRC, vaccines cannot be produced until 2022.
When asked to explain the difference between the promised production numbers and what happened, the Prime Minister’s office did not reply. The Prime Minister and his ministers rejected interview requests about Canada’s early vaccine production plans, including the NRC and CanSino.
NRC has said US-based vaccine developer Novavax will become its new partner for the facility, but Health Canada has not yet approved its vaccine.
The NRC declined interview requests with its officials but provided written answers to the questions.
“One of the most advanced at the time – it was considered prudent to use the opportunity to gain access to the CanSino vaccine candidate,” the NRC said.
The NRC acknowledged that the failure of the Casino agreement forced the cancellation of its original clinical trial production plans.
“There is no doubt that this has pushed us back years,” Davis said. “When you’re in a global epidemic, it’s deadly. It costs lives.”
Casino conquers Fifth Estate Interview
U is proud of Carcino’s COVID-19 vaccine that is getting millions of weapons around the world.
Sitting with the CEO of the company Fifth Estate For an extensive interview, he discussed his roots in the Canadian pharmaceutical industry, his family still living in Toronto, and his research work with the Chinese military.
“I see them as collaborators. It’s just a research institute, right?” U said.
But when the cameras were turned off, he was clearly not happy with how the interview unfolded.
When freelance camera crews packed up their gear at the Casino Biologics offices in Tianjin, China, company officials seized the recording of the interview.
CanSino deleted half of the recording 10 days later before returning it. Fortunately, Fifth Estate The entire interview was recorded from Toronto.
Chinese authorities may have rejected a carcino vaccine candidate for cancino, but Canadian scientists and laboratories are still supporting the casino’s Covid-19 vaccine, which is used in at least nine countries.
The Center for Vaccineology in Halifax continues to work for the casino, with Halperin conducting Phase 3 global trials on a $ 3.5 million contract.
“At this stage, the vaccine will never come to Canada. It will be used in other places around the world, but not in Canada,” Halperin said. “I see this as part of Canada’s contribution to the global war against Kovid-19.”
- If you have suggestions for this or any other story, please contact the Fifth Estate Team.